Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $1.34 Analyst target: $25.50 Upside: 1802.99%
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington.
See the full interactive analysis & chart →Informational only — not investment advice.